HRP20200096T1 - Oralne formulacije analoga citidina i postupci za njihovu upotrebu - Google Patents
Oralne formulacije analoga citidina i postupci za njihovu upotrebu Download PDFInfo
- Publication number
- HRP20200096T1 HRP20200096T1 HRP20200096TT HRP20200096T HRP20200096T1 HR P20200096 T1 HRP20200096 T1 HR P20200096T1 HR P20200096T T HRP20200096T T HR P20200096TT HR P20200096 T HRP20200096 T HR P20200096T HR P20200096 T1 HRP20200096 T1 HR P20200096T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical composition
- composition
- use according
- cancer
- subject
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 13
- 238000000034 method Methods 0.000 title claims 5
- 238000009472 formulation Methods 0.000 title claims 3
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical class O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 claims 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 229960002756 azacitidine Drugs 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 239000003961 penetration enhancing agent Substances 0.000 claims 2
- 229940113116 polyethylene glycol 1000 Drugs 0.000 claims 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 2
- UCKYOOZPSJFJIZ-FMDGEEDCSA-N (4r)-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 UCKYOOZPSJFJIZ-FMDGEEDCSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102100026846 Cytidine deaminase Human genes 0.000 claims 1
- 108010031325 Cytidine deaminase Proteins 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229960000913 crospovidone Drugs 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 229940057948 magnesium stearate Drugs 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 229960001855 mannitol Drugs 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (14)
1. Farmaceutski sastav za upotrebu u postupku liječenja subjekta koji ima karcinom, gdje spomenuti postupak obuhvaća oralnu primjenu spomenutog farmaceutskog sastava jednom dnevno, i gdje spomenuti farmaceutski sastav obuhvaća terapeutski efikasnu količinu 5-azacitidina i sastav je s trenutnim oslobađanjem.
2. Farmaceutski sastav za upotrebu prema zahtjevu 1, gdje spomenuti postupak obuhvaća dnevno davanje subjektu spomenutog farmaceutskog sastava tijekom 7 ili više dana.
3. Farmaceutski sastav za upotrebu prema zahtjevu 1 ili zahtjevu 2, gdje spomenuti postupak dalje obuhvaća davanje dodatnog terapeutskog sredstva.
4. Farmaceutski sastav za upotrebu prema bilo kojem od zahtjeva 1 do 3, gdje je karcinom mijelodisplastični sindrom, akutna mijeloična leukemija, karcinom pluća nemalih stanica, karcinom jajnika, karcinom gušterače ili kolorektalni karcinom.
5. Farmaceutski sastav za upotrebu prema bilo kojem od zahtjeva 1 do 4, gdje je količina 5-azacitidina oko 40 mg, oko 400 mg, ili oko 1000 mg.
6. Farmaceutski sastav za upotrebu prema bilo kojem od zahtjeva 1 do 5, gdje sastav nije gastrorezistentno obložena.
7. Farmaceutski sastav za upotrebu prema bilo kojem od zahtjeva 1 do 6, gdje je sastavu pojedinačnom doznom obliku.
8. Farmaceutski sastav za upotrebu prema bilo kojem od zahtjeva 1 do 7, gdje je sastav tableta ili kapsula.
9. Farmaceutski sastav za upotrebu prema bilo kojem od zahtjeva 1 do 8, gdje sastav dalje sadrži pomoćnu tvar izabranu između manitola, mikrokristalne celuloze, krospovidona i magnezijeva stearata.
10. Farmaceutski sastav za upotrebu prema bilo kojem od zahtjeva 1 do 9, gdje sastav dalje obuhvaća pojačivač permeacije.
11. Farmaceutski sastav za upotrebu prema zahtjevu 10, gdje je pojačivač permeacije d-alfa-tokoferil polietilen glikol 1000 sukcinat, opcionalno gdje je d-alfa-tokoferil polietilen glikol 1000 sukcinat prisutan u formulaciji pri oko 2% mase relativno u odnosu na ukupnu masu formulacije.
12. Farmaceutski sastav za upotrebu prema bilo kojem od zahtjeva 1 do 11, koji je u osnovi bez inhibitora citidin deaminaze ili koji je u osnovi bez tetrahidrouridina.
13. Farmaceutski sastav za upotrebu prema bilo kojem od zahtjeva 1 do 12, gdje sastav postiže vrijednost površine ispod krivulje od bar oko 200 ng-hr/mL ili bar oko 400 ng-hr/mL poslije oralnog uzimanja, ili gdje sastav postiže maksimalnu koncentraciju u plazmi od bar oko 100 ng/mL ili bar oko 200 ng/mL poslije oralnog uzimanja, ili gdje sastav postiže vrijeme maksimalne koncentracije u plazmi manje od oko 60 minuta, manje od oko 90 minuta, ili manje od oko 180 minuta poslije oralnog uzimanja subjekta.
14. Sastav prema bilo kojem od zahtjeva 1 do 13, gdje je subjekt čovjek.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5360908P | 2008-05-15 | 2008-05-15 | |
| US20114508P | 2008-12-05 | 2008-12-05 | |
| US15787509P | 2009-03-05 | 2009-03-05 | |
| EP13182721.4A EP2695609B1 (en) | 2008-05-15 | 2009-05-14 | Oral formulations of cytidine analogs and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20200096T1 true HRP20200096T1 (hr) | 2020-04-03 |
Family
ID=40941609
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231439TT HRP20231439T1 (hr) | 2008-05-15 | 2009-05-14 | Oralne formulacije citidinskih analoga i postupci za njihovu uporabu |
| HRP20221064TT HRP20221064T1 (hr) | 2008-05-15 | 2009-05-14 | Oralne formulacije citidinskih analoga i postupci njihove uporabe |
| HRP20190100TT HRP20190100T1 (hr) | 2008-05-15 | 2019-01-16 | Oralne formulacije analoga citidina i postupci za njihovu upotrebu |
| HRP20200096TT HRP20200096T1 (hr) | 2008-05-15 | 2020-01-21 | Oralne formulacije analoga citidina i postupci za njihovu upotrebu |
| HRP20211398TT HRP20211398T1 (hr) | 2008-05-15 | 2021-09-02 | Oralne formulacije citidinskih analoga i postupci njihove uporabe |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231439TT HRP20231439T1 (hr) | 2008-05-15 | 2009-05-14 | Oralne formulacije citidinskih analoga i postupci za njihovu uporabu |
| HRP20221064TT HRP20221064T1 (hr) | 2008-05-15 | 2009-05-14 | Oralne formulacije citidinskih analoga i postupci njihove uporabe |
| HRP20190100TT HRP20190100T1 (hr) | 2008-05-15 | 2019-01-16 | Oralne formulacije analoga citidina i postupci za njihovu upotrebu |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211398TT HRP20211398T1 (hr) | 2008-05-15 | 2021-09-02 | Oralne formulacije citidinskih analoga i postupci njihove uporabe |
Country Status (34)
| Country | Link |
|---|---|
| US (11) | US8846628B2 (hr) |
| EP (6) | EP3782612B1 (hr) |
| JP (3) | JP2011520880A (hr) |
| KR (1) | KR101633134B1 (hr) |
| CN (3) | CN102099018B (hr) |
| AR (1) | AR071808A1 (hr) |
| AU (3) | AU2009246926B2 (hr) |
| BR (1) | BRPI0912717A2 (hr) |
| CA (3) | CA3094590A1 (hr) |
| CL (2) | CL2009001170A1 (hr) |
| CO (1) | CO6300930A2 (hr) |
| CR (1) | CR11789A (hr) |
| CY (3) | CY1121350T1 (hr) |
| DK (5) | DK3692983T3 (hr) |
| EC (1) | ECSP10010665A (hr) |
| ES (5) | ES2774226T3 (hr) |
| FI (1) | FI3782612T3 (hr) |
| HR (5) | HRP20231439T1 (hr) |
| HU (5) | HUE059635T2 (hr) |
| IL (2) | IL238087B (hr) |
| LT (5) | LT3782612T (hr) |
| MX (2) | MX363023B (hr) |
| MY (1) | MY161593A (hr) |
| NI (1) | NI201000193A (hr) |
| NZ (3) | NZ602833A (hr) |
| PE (2) | PE20091971A1 (hr) |
| PL (5) | PL3782612T3 (hr) |
| PT (5) | PT2299984T (hr) |
| RU (3) | RU2476207C2 (hr) |
| SG (1) | SG193206A1 (hr) |
| SI (5) | SI3692983T1 (hr) |
| TW (3) | TW201513869A (hr) |
| WO (1) | WO2009139888A1 (hr) |
| ZA (1) | ZA201008229B (hr) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| US8404717B2 (en) * | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes using lenalidomide |
| US11116782B2 (en) | 2002-10-15 | 2021-09-14 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| US6943249B2 (en) * | 2003-03-17 | 2005-09-13 | Ash Stevens, Inc. | Methods for isolating crystalline Form I of 5-azacytidine |
| US6887855B2 (en) | 2003-03-17 | 2005-05-03 | Pharmion Corporation | Forms of 5-azacytidine |
| US8497292B2 (en) * | 2005-12-28 | 2013-07-30 | Translational Therapeutics, Inc. | Translational dysfunction based therapeutics |
| WO2009058394A1 (en) * | 2007-11-01 | 2009-05-07 | Celgene Corporation | Cytidine analogs for treatment of myelodysplastic syndromes |
| CN102099018B (zh) | 2008-05-15 | 2016-01-13 | 细胞基因公司 | 胞苷类似物的口服制剂和其使用方法 |
| US20150290228A1 (en) * | 2008-05-15 | 2015-10-15 | Jay T. BACKSTROM | Oral formulations of cytidine analogs and methods of use thereof |
| JP6063628B2 (ja) * | 2009-02-10 | 2017-01-18 | セルジーン インターナショナル サルル | ５−アザシチジンを用いる、非小細胞肺癌の治療方法 |
| US8491927B2 (en) | 2009-12-02 | 2013-07-23 | Nimble Epitech, Llc | Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor |
| AU2011264590B2 (en) * | 2010-06-07 | 2016-12-15 | Abraxis Bioscience, Llc | Combination therapy methods for treating proliferative diseases |
| US20110301102A1 (en) * | 2010-06-07 | 2011-12-08 | Telik, Inc. | Compositions and methods for treating myelodysplastic syndrome |
| US8759303B2 (en) | 2010-06-07 | 2014-06-24 | Telik, Inc. | Compositions and methods for treating myelodysplastic syndrome |
| CA2825152A1 (en) * | 2011-01-31 | 2012-08-09 | Celgene Corporation | Pharmaceutical compositions of cytidine analogs and methods of use thereof |
| EP2481813A1 (en) * | 2011-02-01 | 2012-08-01 | Centro di Riferimento Oncologico - Istituto Nazionale Tumori - Aviano | Markers of cutaneous melanoma and uses thereof |
| KR20140019820A (ko) | 2011-03-31 | 2014-02-17 | 셀진 인터내셔널 에스에이알엘 | 5-아자시티딘의 합성 |
| CA2853949A1 (en) * | 2011-11-01 | 2013-05-10 | Celgene Corporation | Methods for treating cancers using oral formulations of cytidine analogs |
| AU2012321106C1 (en) | 2011-11-03 | 2016-11-24 | Takeda Pharmaceutical Company Limited | Administration of NEDD8-activating enzyme inhibitor and hypomethylating agent |
| US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
| MX2015000804A (es) * | 2012-07-20 | 2016-03-11 | Star Biotechnology Llc | Composiciones y metodos para tratar el sarcoma de ewing y otros trastornos relacionados con ews-fli1. |
| US20150031627A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| JP6564796B2 (ja) | 2014-03-14 | 2019-08-21 | アジオス ファーマシューティカルズ， インコーポレイテッド | 治療活性化合物の医薬組成物 |
| WO2015195634A1 (en) | 2014-06-17 | 2015-12-23 | Celgne Corporation | Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine |
| EA201790439A1 (ru) | 2014-08-22 | 2017-07-31 | Селджин Корпорейшн | Способы лечения множественной миеломы с применением иммуномодулирующих соединений в комбинации с антителами |
| LT3362066T (lt) | 2015-10-15 | 2022-02-10 | Les Laboratoires Servier Sas | Kombinuota terapija, skirta piktybinių susirgimų gydymui |
| ES2862730T3 (es) * | 2015-10-15 | 2021-10-07 | Celgene Corp | Combinación de un inhibidor de isocitrato deshidrogenasa 2 mutante con azacitidina y su uso para el tratamiento de la leucemia mielógena aguda |
| EP3362065B1 (en) | 2015-10-15 | 2024-04-03 | Les Laboratoires Servier | Combination therapy comprising ivosidenib, cytarabine and daunorubicin or idarubicin for treating acute myelogenous leukemia |
| JP7194021B2 (ja) | 2015-12-03 | 2022-12-21 | エピデスティニー，インコーポレイテッド | デシタビン、５アザシチジンおよびテトラヒドロウリジンを含有する組成物およびその使用 |
| WO2017180489A1 (en) | 2016-04-12 | 2017-10-19 | The Johns Hopkins University | Quantitative determination of nucleoside analogue drugs in genomic dna or rna |
| US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
| EA039874B1 (ru) * | 2019-06-06 | 2022-03-22 | Общество С Ограниченной Ответственностью "Технология Лекарств" | Композиция помалидомида для лечения заболеваний, ассоциированных с фактором некроза опухоли (фно) |
| BR112021025375A2 (pt) | 2019-06-20 | 2022-02-01 | Celgene Corp | Azacitidina em combinação com venetoclax, gilteritinibe, midostaurina ou outros compostos para tratamento de leucemia ou síndrome mielodisplástica |
| BR112022007179A2 (pt) | 2019-10-21 | 2022-08-23 | Novartis Ag | Inibidores de tim-3 e usos dos mesmos |
| TW202128166A (zh) | 2019-10-21 | 2021-08-01 | 瑞士商諾華公司 | 組合療法 |
| EP4077389A1 (en) | 2019-12-20 | 2022-10-26 | Novartis AG | Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome |
| CN114980902A (zh) | 2020-01-17 | 2022-08-30 | 诺华股份有限公司 | 用于治疗骨髓增生异常综合征或慢性粒单核细胞白血病的包含tim-3抑制剂和低甲基化药物的组合 |
| WO2022020747A1 (en) | 2020-07-23 | 2022-01-27 | Southern Research Institute | Polymorophs of 5-aza-4'-thio-2-deoxycytidine |
| EP4262812A1 (en) | 2020-12-18 | 2023-10-25 | Southern Research Institute | 6-aza-nucleoside prodrugs as antiviral agents for treating virus infections |
| WO2022192621A1 (en) | 2021-03-12 | 2022-09-15 | Celgene Corporation | Methods for using a hypomethylating agent to treat diseases and disorders based on gene mutation profiles |
| WO2023069529A1 (en) | 2021-10-19 | 2023-04-27 | Akirabio, Inc. | Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2913408A (en) | 1956-12-28 | 1959-11-17 | Dow Chemical Co | Corrosion inhibitors for ferrous metals in aqueous solutions of non-oxidizing acids |
| GB1050899A (hr) | 1963-12-22 | |||
| CH527207A (de) | 1968-05-08 | 1972-08-31 | Ceskoslovenska Akademie Ved | Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen |
| CH507969A (de) | 1968-11-12 | 1971-05-31 | Ceskoslovenska Akademie Ved | Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen |
| DE2012888C3 (de) | 1970-03-14 | 1981-04-02 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden |
| FR2123632A6 (en) | 1971-01-26 | 1972-09-15 | Ceskoslovenska Akademie Ved | Prepn of 5-azacytosines and 5-azacytidines - from bis trimethylsilyl-5-azacytosine |
| DE2122991C2 (de) | 1971-05-04 | 1982-06-09 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Verfahren zur Herstellung von Cytosin- und 6-Azacytosinnucleosiden |
| DE2508312A1 (de) | 1975-02-24 | 1976-09-02 | Schering Ag | Neues verfahren zur herstellung von nucleosiden |
| DE2757365A1 (de) | 1977-12-20 | 1979-06-21 | Schering Ag | Neues verfahren zur herstellung von nucleosiden |
| JPS59151784U (ja) | 1983-03-30 | 1984-10-11 | 日産自動車株式会社 | トラツクのリヤボデイ構造 |
| US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| EP0397042B1 (de) | 1989-05-10 | 1995-08-16 | F. Hoffmann-La Roche Ag | Herstellung von Isochinolinderivaten |
| US5360352A (en) | 1992-12-24 | 1994-11-01 | The Whitaker Corporation | Wire retainer for current mode coupler |
| US6432924B1 (en) | 1993-12-26 | 2002-08-13 | East Carolina University | Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase |
| GB9412394D0 (en) | 1994-06-21 | 1994-08-10 | Danbiosyst Uk | Colonic drug delivery composition |
| US5700640A (en) | 1994-09-16 | 1997-12-23 | Basf Aktiengesellschaft | Inducers of gamma globin gene expression and screening assays therefor |
| US5539209A (en) | 1994-10-17 | 1996-07-23 | Trojan Technologies Inc. | Method of cleaning fouling materials from a radiation module |
| PL187107B1 (pl) | 1996-10-16 | 2004-05-31 | Icn Pharmaceuticals | L-nukleozydy monocykliczne, kompozycja farmaceutyczna zawierająca te związki oraz ich zastosowanie |
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| CA2290624C (en) | 1997-06-06 | 2006-12-05 | John W. Shell | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
| US6566395B1 (en) | 1999-05-25 | 2003-05-20 | Biomedicines, Inc. | Methods of treating proliferative disorders |
| US6803195B1 (en) | 1999-07-02 | 2004-10-12 | Ramot At Tel-Aviv University Ltd. | Facile detection of cancer and cancer risk based on level of coordination between alleles |
| KR20020012006A (ko) | 1999-07-16 | 2002-02-09 | 오오쯔끼쥰조 | 점막 흡수용 글리시리진 제제 |
| PT1251832E (pt) | 2000-02-04 | 2007-01-31 | Depomed Inc | Forma de dosagem constituída por invólucro-e-núcleo que conduz a uma libertação do fármaco de ordem zero |
| GB0102342D0 (en) | 2001-01-30 | 2001-03-14 | Smithkline Beecham Plc | Pharmaceutical formulation |
| EP1399159A4 (en) | 2001-06-01 | 2007-02-14 | Cytovia Inc | 4-SUBSTITUTE-1- (ARYLMETHYLIDENE) THIOSEMICARBAZIDE, 4-SUBSTITUTE-1- (ARYLCARBONYL) THIOSEMICARBAZIDE AND ANALOGUES AS ACTIVATORS OF APOPTOSIS CAPSASES AND TRIGS, AND USE THEREOF |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| US20030220254A1 (en) | 2002-03-29 | 2003-11-27 | Texas Tech University System | Composition and method for preparation of an oral dual controlled release formulation of a protein and inhibitor |
| CA2499036A1 (en) | 2002-09-24 | 2004-04-08 | Koronis Pharmaceuticals, Incorporated | 1,3,5-triazines for treatment of viral diseases |
| US7189740B2 (en) * | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| US20040162263A1 (en) | 2002-10-31 | 2004-08-19 | Supergen, Inc., A Delaware Corporation | Pharmaceutical formulations targeting specific regions of the gastrointesinal tract |
| CN100364531C (zh) | 2002-12-18 | 2008-01-30 | 西托维亚公司 | 3,5－二取代－[1,2,4]－二唑及类似物和其用途 |
| US6887855B2 (en) | 2003-03-17 | 2005-05-03 | Pharmion Corporation | Forms of 5-azacytidine |
| US7038038B2 (en) | 2003-03-17 | 2006-05-02 | Pharmion Corporation | Synthesis of 5-azacytidine |
| US6943249B2 (en) | 2003-03-17 | 2005-09-13 | Ash Stevens, Inc. | Methods for isolating crystalline Form I of 5-azacytidine |
| AU2004270150C1 (en) * | 2003-08-29 | 2011-07-14 | Merck Hdac Research, Llc | Combination methods of treating cancer |
| US7192781B2 (en) | 2004-04-13 | 2007-03-20 | Pharmion Corporation | Methods for stabilizing 5-azacytidine in plasma |
| US20060063735A1 (en) | 2004-09-17 | 2006-03-23 | Supergen, Inc. | Salts of 5-azacytidine |
| US20060069060A1 (en) | 2004-09-27 | 2006-03-30 | Sanjeev Redkar | Salts of decitabine |
| CN100374160C (zh) * | 2004-11-22 | 2008-03-12 | 山东蓝金生物工程有限公司 | 一种含抗代谢类药物的抗癌药物组合物 |
| US20060128654A1 (en) | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of cytidine analogs and derivatives |
| DK2301531T3 (en) | 2005-02-18 | 2018-07-30 | Abraxis Bioscience Llc | COMBINATIONS AND WAYS FOR ADMINISTRATING THERAPEUTIC SUBSTANCES AND COMBINATION THERAPY |
| CN104688697A (zh) | 2005-03-07 | 2015-06-10 | 拜尔健康护理有限责任公司 | 用于治疗癌症的包含ω-羧芳基取代的二苯基脲的药物组合物 |
| CN100500212C (zh) * | 2005-04-06 | 2009-06-17 | 山东蓝金生物工程有限公司 | 一种抗实体肿瘤药物组合物 |
| US8058260B2 (en) | 2006-05-22 | 2011-11-15 | Xenoport, Inc. | 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof |
| WO2008028193A2 (en) | 2006-09-01 | 2008-03-06 | Pharmion Corporation | Colon-targeted oral formulations of cytidine analogs |
| EP2118117A2 (en) | 2007-01-11 | 2009-11-18 | IVAX Pharmaceuticals s.r.o. | Solid state forms of 5-azacytidine and processes for preparation thereof |
| WO2008092127A1 (en) | 2007-01-25 | 2008-07-31 | Nevada Cancer Institute | Use of acetylated or esterificated azacytidine, decitabine, or other nucleoside analogs as oral agents for the treatment of tumors or other dysplastic syndromes sensitive to hypomethylating agents |
| JP5173298B2 (ja) | 2007-07-25 | 2013-04-03 | キヤノン株式会社 | プリント配線板およびそれを用いた電子機器 |
| US20110288042A1 (en) | 2007-08-02 | 2011-11-24 | Chemagis Ltd. | Stable highly pure azacitidine and preparation methods therefor |
| MX2010003261A (es) | 2007-09-26 | 2010-08-18 | Sinai School Medicine | Analogos de azacitidina y usos de los mismos. |
| EP2048151A1 (en) | 2007-10-10 | 2009-04-15 | Cilag AG | Method for producing nucleosides by direct glycosylation of the nucleoside base |
| JO2778B1 (en) | 2007-10-16 | 2014-03-15 | ايساي انك | Certain vehicles, installations and methods |
| WO2009058394A1 (en) | 2007-11-01 | 2009-05-07 | Celgene Corporation | Cytidine analogs for treatment of myelodysplastic syndromes |
| CN102099018B (zh) * | 2008-05-15 | 2016-01-13 | 细胞基因公司 | 胞苷类似物的口服制剂和其使用方法 |
| WO2010014883A2 (en) | 2008-08-01 | 2010-02-04 | Dr. Reddy's Laboratories Ltd. | Azacitidine process and polymorphs |
| EP2520581A1 (en) | 2008-08-06 | 2012-11-07 | Sicor, Inc. | Method for the determination the purity of 5-Azacytidine |
| AR073003A1 (es) | 2008-08-08 | 2010-10-06 | Scinopharm Taiwan Ltd | Proceso para preparar 5-azacitosina nucleosidos y sus derivados |
| CA2744158A1 (en) | 2008-11-22 | 2010-05-27 | Genentech, Inc. | Anti-angiogenesis therapy for the treatment of breast cancer |
| US20110042247A1 (en) | 2009-06-25 | 2011-02-24 | Chandrasekhar Kocherlakota | Formulations of azacitidine and its derivatives |
| WO2011014541A1 (en) | 2009-07-30 | 2011-02-03 | Eagle Pharmaceuticals, Inc. | Stable formulations of azacitidine |
| IT1399195B1 (it) | 2010-03-30 | 2013-04-11 | Chemi Spa | Processo per la sintesi di azacitidina e decitabina |
| CA2825152A1 (en) | 2011-01-31 | 2012-08-09 | Celgene Corporation | Pharmaceutical compositions of cytidine analogs and methods of use thereof |
| KR20140019820A (ko) | 2011-03-31 | 2014-02-17 | 셀진 인터내셔널 에스에이알엘 | 5-아자시티딘의 합성 |
| WO2013022872A1 (en) | 2011-08-10 | 2013-02-14 | Celgene Corporation | Gene methylation biomarkers and methods of use thereof |
| CA2853949A1 (en) | 2011-11-01 | 2013-05-10 | Celgene Corporation | Methods for treating cancers using oral formulations of cytidine analogs |
-
2009
- 2009-05-14 CN CN200980127929.8A patent/CN102099018B/zh not_active Ceased
- 2009-05-14 DK DK19213148.0T patent/DK3692983T3/da active
- 2009-05-14 EP EP20201143.3A patent/EP3782612B1/en active Active
- 2009-05-14 LT LTEP20201143.3T patent/LT3782612T/lt unknown
- 2009-05-14 DK DK20201105.2T patent/DK3782611T3/da active
- 2009-05-14 LT LTEP09746975.3T patent/LT2299984T/lt unknown
- 2009-05-14 HU HUE20201105A patent/HUE059635T2/hu unknown
- 2009-05-14 CN CN201510982946.7A patent/CN105535008A/zh active Pending
- 2009-05-14 EP EP13182721.4A patent/EP2695609B1/en active Active
- 2009-05-14 US US12/466,213 patent/US8846628B2/en active Active
- 2009-05-14 CN CN201310363158.0A patent/CN103479586B/zh not_active Ceased
- 2009-05-14 SI SI200932143T patent/SI3692983T1/sl unknown
- 2009-05-14 ES ES13182721T patent/ES2774226T3/es active Active
- 2009-05-14 NZ NZ602833A patent/NZ602833A/en unknown
- 2009-05-14 SI SI200931918T patent/SI2299984T1/sl unknown
- 2009-05-14 ES ES09746975T patent/ES2712506T3/es active Active
- 2009-05-14 PT PT09746975T patent/PT2299984T/pt unknown
- 2009-05-14 MX MX2014010978A patent/MX363023B/es unknown
- 2009-05-14 HR HRP20231439TT patent/HRP20231439T1/hr unknown
- 2009-05-14 SI SI200932188T patent/SI3782612T1/sl unknown
- 2009-05-14 PT PT202011433T patent/PT3782612T/pt unknown
- 2009-05-14 EP EP23207760.2A patent/EP4327888A3/en active Pending
- 2009-05-14 PL PL20201143.3T patent/PL3782612T3/pl unknown
- 2009-05-14 AU AU2009246926A patent/AU2009246926B2/en active Active
- 2009-05-14 PL PL09746975T patent/PL2299984T3/pl unknown
- 2009-05-14 CL CL2009001170A patent/CL2009001170A1/es unknown
- 2009-05-14 NZ NZ623495A patent/NZ623495A/en unknown
- 2009-05-14 ES ES19213148T patent/ES2893785T3/es active Active
- 2009-05-14 KR KR1020107028070A patent/KR101633134B1/ko active IP Right Grant
- 2009-05-14 ES ES20201105T patent/ES2927556T3/es active Active
- 2009-05-14 JP JP2011509487A patent/JP2011520880A/ja not_active Withdrawn
- 2009-05-14 CA CA3094590A patent/CA3094590A1/en not_active Abandoned
- 2009-05-14 BR BRPI0912717-8A2A patent/BRPI0912717A2/pt not_active Application Discontinuation
- 2009-05-14 EP EP20201105.2A patent/EP3782611B1/en active Active
- 2009-05-14 DK DK13182721.4T patent/DK2695609T3/da active
- 2009-05-14 HU HUE20201143A patent/HUE064677T2/hu unknown
- 2009-05-14 CA CA2761582A patent/CA2761582C/en active Active
- 2009-05-14 PT PT131827214T patent/PT2695609T/pt unknown
- 2009-05-14 RU RU2010151428/15A patent/RU2476207C2/ru active
- 2009-05-14 NZ NZ589437A patent/NZ589437A/xx unknown
- 2009-05-14 LT LTEP19213148.0T patent/LT3692983T/lt unknown
- 2009-05-14 SI SI200932170T patent/SI3782611T1/sl unknown
- 2009-05-14 PT PT202011052T patent/PT3782611T/pt unknown
- 2009-05-14 HU HUE13182721A patent/HUE047707T2/hu unknown
- 2009-05-14 LT LTEP13182721.4T patent/LT2695609T/lt unknown
- 2009-05-14 HU HUE19213148A patent/HUE055911T2/hu unknown
- 2009-05-14 SG SG2013061601A patent/SG193206A1/en unknown
- 2009-05-14 SI SI200932020T patent/SI2695609T1/sl unknown
- 2009-05-14 PL PL13182721T patent/PL2695609T3/pl unknown
- 2009-05-14 FI FIEP20201143.3T patent/FI3782612T3/fi active
- 2009-05-14 CA CA3094580A patent/CA3094580C/en active Active
- 2009-05-14 PL PL19213148T patent/PL3692983T3/pl unknown
- 2009-05-14 PT PT192131480T patent/PT3692983T/pt unknown
- 2009-05-14 ES ES20201143T patent/ES2969144T3/es active Active
- 2009-05-14 EP EP09746975.3A patent/EP2299984B1/en active Active
- 2009-05-14 WO PCT/US2009/002999 patent/WO2009139888A1/en active Application Filing
- 2009-05-14 HR HRP20221064TT patent/HRP20221064T1/hr unknown
- 2009-05-14 LT LTEP20201105.2T patent/LT3782611T/lt unknown
- 2009-05-14 HU HUE09746975A patent/HUE042825T2/hu unknown
- 2009-05-14 MX MX2010012470A patent/MX2010012470A/es active IP Right Grant
- 2009-05-14 EP EP19213148.0A patent/EP3692983B1/en active Active
- 2009-05-14 DK DK09746975.3T patent/DK2299984T3/en active
- 2009-05-14 DK DK20201143.3T patent/DK3782612T3/da active
- 2009-05-14 PL PL20201105.2T patent/PL3782611T3/pl unknown
- 2009-05-14 MY MYPI2010005331A patent/MY161593A/en unknown
- 2009-05-15 TW TW104100098A patent/TW201513869A/zh unknown
- 2009-05-15 PE PE2009000685A patent/PE20091971A1/es not_active Application Discontinuation
- 2009-05-15 TW TW098116326A patent/TWI522103B/zh active
- 2009-05-15 AR ARP090101759A patent/AR071808A1/es not_active Application Discontinuation
- 2009-05-15 TW TW105141639A patent/TWI618538B/zh active
- 2009-05-15 PE PE2014002005A patent/PE20142440A1/es not_active Application Discontinuation
-
2010
- 2010-11-12 CR CR11789A patent/CR11789A/es unknown
- 2010-11-12 NI NI201000193A patent/NI201000193A/es unknown
- 2010-11-14 IL IL238087A patent/IL238087B/en active IP Right Grant
- 2010-11-14 IL IL209307A patent/IL209307A/en active IP Right Grant
- 2010-11-17 ZA ZA2010/08229A patent/ZA201008229B/en unknown
- 2010-12-07 EC EC2010010665A patent/ECSP10010665A/es unknown
- 2010-12-15 CO CO10157384A patent/CO6300930A2/es not_active Application Discontinuation
-
2012
- 2012-11-09 RU RU2012147739/15A patent/RU2012147739A/ru unknown
-
2013
- 2013-04-05 AU AU2013202665A patent/AU2013202665B2/en active Active
- 2013-04-22 CL CL2013001097A patent/CL2013001097A1/es unknown
-
2014
- 2014-08-19 US US14/463,424 patent/US20150056280A1/en not_active Abandoned
- 2014-12-12 JP JP2014251911A patent/JP6105547B2/ja active Active
-
2015
- 2015-05-27 AU AU2015202884A patent/AU2015202884B2/en active Active
- 2015-06-30 US US14/788,606 patent/US20150374732A1/en not_active Abandoned
-
2017
- 2017-03-02 JP JP2017039320A patent/JP6426778B2/ja active Active
- 2017-12-07 US US15/835,088 patent/US10220050B2/en active Active
-
2018
- 2018-03-15 RU RU2018109222A patent/RU2765076C2/ru active
-
2019
- 2019-01-09 US US16/244,014 patent/US10463683B2/en active Active
- 2019-01-16 HR HRP20190100TT patent/HRP20190100T1/hr unknown
- 2019-02-25 CY CY20191100231T patent/CY1121350T1/el unknown
- 2019-09-25 US US16/582,779 patent/US10646503B2/en active Active
-
2020
- 2020-01-21 HR HRP20200096TT patent/HRP20200096T1/hr unknown
- 2020-02-24 CY CY20201100168T patent/CY1122681T1/el unknown
- 2020-03-27 US US16/833,410 patent/US20200316099A1/en not_active Abandoned
-
2021
- 2021-09-02 HR HRP20211398TT patent/HRP20211398T1/hr unknown
- 2021-10-20 CY CY20211100917T patent/CY1124720T1/el unknown
- 2021-11-22 US US17/533,033 patent/US11571436B2/en active Active
- 2021-12-16 US US17/553,456 patent/US20220105118A1/en not_active Abandoned
-
2022
- 2022-11-10 US US17/984,939 patent/US20230241086A1/en active Pending
-
2023
- 2023-04-24 US US18/138,473 patent/US20230255996A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200096T1 (hr) | Oralne formulacije analoga citidina i postupci za njihovu upotrebu | |
| CY1119140T1 (el) | Συνθεσεις αντικωδικευσης και μεθοδοι κατασκευης και χρησης τους | |
| WO2006123357A3 (en) | Oral controlled release composition containing levetiracetam | |
| EA200900264A1 (ru) | Композиции флибансерина и способ их приготовления | |
| CN109195981A (zh) | 作为抗癌剂的氨基磷酸酯核苷衍生物 | |
| HRP20150644T1 (hr) | Metoda za lijeäśenje atrijalne fibrilacije | |
| CA2662278A1 (en) | Methods and compositions for increasing patient tolerability during myocardial imaging methods | |
| EP2603222B1 (en) | Combinatory cancer treatment | |
| JP2010502649A5 (hr) | ||
| MX2009012155A (es) | Combinación farmacéutica sinérgica para el tratamiento de cáncer. | |
| RU2007114908A (ru) | Применение агонистов аденозиновых рецепторов a2a | |
| AR075735A1 (es) | Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso | |
| WO2009088838A3 (en) | Triarylmethane analogs and their use in treating cancers | |
| MY173881A (en) | Oral dosage forms of bendamustine and therapeutic use thereof | |
| TW200503775A (en) | Pharmaceutical composition and method for treating | |
| HRP20192189T1 (hr) | Doziranja i terapijske primjene l-4-klorokinurenina | |
| JP2013508289A5 (hr) | ||
| CA3008749A1 (en) | Treatment of ovarian cancer or biliary tract cancer with a combination of gemcitabine-(phenyl-benzoxy-l-alaninyl)]-phosphate and cisplatin | |
| Wu et al. | Short-term safety, tolerability, and pharmacokinetics of MRX-I, an oxazolidinone antibacterial agent, in healthy Chinese subjects | |
| US20170232032A1 (en) | Pharmaceutical compositions for treating ebola virus disease | |
| NO20080244L (no) | Doseringsstyring for prasugrel | |
| HRP20130959T1 (hr) | Antikancerozni spojevi i farmaceutski pripravci koji ih sadrže | |
| WO2018115888A1 (en) | Novel formulations of aprepitant | |
| ZA200403737B (en) | Use of an farsenyl protein transferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer. | |
| Parthasarathi et al. | Analysis of pharmacokinetic & pharmacodynamic models in oral and transdermal dosage forms |